LILRB4 and melanoma: Roles of m6A erasers: Yang et al. revealed that dysregulation of FTO expression in melanoma reduced the abundance of the m6A modification in the native protumorigenic genes PD1 (PDCD1), SOX10, and CXCR4 in melanoma cells and decreased RNA decay mediated through YTHDF2, ultimately leading to enhanced melanoma cell resistance to anti-PD1 blockade immunotherapy.239 FTO upregulates leukocyte immunoglobulin-like receptor B4 (LILRB4) expression in acute myeloid leukemia (AML), leading to immune response reprogramming.